for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CSL Limited

CSL.AX

Latest Trade

265.50AUD

Change

2.10(+0.80%)

Volume

455,820

Today's Range

263.50

 - 

265.79

52 Week Range

242.00

 - 

332.68

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
263.40
Open
263.97
Volume
455,820
3M AVG Volume
17.60
Today's High
265.79
Today's Low
263.50
52 Week High
332.68
52 Week Low
242.00
Shares Out (MIL)
454.97
Market Cap (MIL)
119,878.50
Forward P/E
39.62
Dividend (Yield %)
1.07

Next Event

Full Year 2021 CSL Ltd Earnings Release

Latest Developments

更多

Seqirus Announces U.S. FDA Approval Of Expanded Age Indication Of Its Cell-Based Quadrivalent Influenza Vaccine

CSL Declares Interim Dividend oF $1.04 Per Share

CSL Half Year NPAT Up 45% To US$1.8 Bln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CSL Limited

CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.

Industry

Biotechnology & Drugs

Contact Info

45 Poplar Road,, Parkville

MELBOURNE, VIC

3052

Australia

+61.3.93891911

https://www.csl.com/

Executive Leadership

Brian Anthony McNamee

Non-Executive Independent Chairman of the Board

Paul Perreault

Chief Executive Officer, Managing Director, Executive Director

Joy Linton

Chief Financial Officer

Paul F McKenzie

Chief Operating Officer

Elizabeth Walker

Chief Human Resource Officer, Executive Vice President

Key Stats

2.14 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

7.6K

2019

8.5K

2020

9.2K

2021(E)

10.0K
EPS (USD)

2018

3.809

2019

4.226

2020

4.615

2021(E)

5.081
Price To Earnings (TTM)
34.54
Price To Sales (TTM)
9.19
Price To Book (MRQ)
11.25
Price To Cash Flow (TTM)
29.49
Total Debt To Equity (MRQ)
75.13
LT Debt To Equity (MRQ)
69.66
Return on Investment (TTM)
20.18
Return on Equity (TTM)
16.78

Latest News

Latest News

UPDATE 1-Australia's CSL half-year profit jumps 45% on strong blood plasma product demand

Australian biotech CSL Ltd on Thursday reported a 45% rise in half-year profit, boosted by higher demand for its vaccines and blood plasma products.

Australia's CSL reports 45% jump in half-year profit

Australian biotech CSL Ltd on Thursday reported a 45% rise in half-year profit, boosted by higher demand for its vaccines and blood plasma products.

UPDATE 4-Australia halts local COVID-19 vaccine development due to false HIV positives

* Canberra to buy more of Oxford, Novavax vaccines (Adds analyst, academic and analyst comment, CSL shares)

Australia's CSL to not go to phase 2 trials for COVID-19 vaccine

Australia's CSL Ltd said on Friday it would not take its COVID-19 vaccine candidate, being developed with the University of Queensland, to phase 2 and 3 clinical trials after trial participants returned false positive HIV test results.

Australia to spend $726 mln underwriting country's biggest vaccine plant

Australia will spend A$1 billion ($726.3 million) underwriting construction of a vaccine manufacturing plant under a deal with a unit of biomedical giant CSL Ltd, guaranteeing supply of flu shots and antivenins, the federal government said on Monday.

ANALYSIS-Australia's star vaccine maker not immune to virus anxiety

Earlier this year, a low-key biomedical firm briefly toppled Australia's biggest bank and miner to become the country's most expensive company and a household brand, thanks to its part in the race to produce a COVID-19 vaccine.

UPDATE 1-Biotech firm CSL raises lower-end profit forecast driven by virus-related demand

Australian biotech giant CSL Ltd raised the lower end of its full-year profit forecast by 3% as demand for vaccines, plasma and recombinant products rise amid the coronavirus pandemic.

Australia's CSL raises lower-end of profit forecast

Australian biotech firm CSL Ltd raised the lower end of its full-year profit forecast by 3% as demand for its plasma and recombinant therapies rise with governments scrambling to protect their populations in light of the COVID-19 pandemic.

UPDATE 2-Australia's CSL to manufacture two COVID-19 vaccines, shares up

* Stock expensive, but CSL rarely ever disappoints - Broker (Recasts with details on vaccines, shares and broker comment)

Australia's CSL signs deals to manufacture two COVID-19 vaccine candidates

Pharmaceutical company CSL Ltd said on Monday it had signed an agreement for the manufacture of an AstraZeneca and Oxford University COVID-19 vaccine, with first doses for Australia expected by early 2021 if trials prove successful.

Australian shares end at over 5-month high as CSL, financials gain

Australian shares closed at a more than five-month high on Wednesday, boosted by gains in drugmaker CSL Ltd and financial stocks, with lower infections of the novel coronavirus in the country aiding sentiment.

UPDATE 3-Australia's CSL eyes COVID-19 vaccine by mid-2021 as it beats profit forecast

Australian biotech giant CSL Ltd raised hopes on Wednesday of delivering a coronavirus vaccine within a year as annual profit outstripped a forecast, thanks to heavy demand for inoculation and blood plasma products that sent shares soaring.

Australia's CSL full-year profit jumps 17% on higher demand for drugs

CSL Ltd, Australia's biggest biotech firm, on Wednesday reported a 17% rise in annual profit, boosted by strong demand for immunoglobulin drugs and other products.

BRIEF-CSL Enters Partnership With Thermo Fisher Scientific

* ENTERED INTO A STRATEGIC PARTNERSHIP WITH THERMO FISHER SCIENTIFIC

Australia's CSL to start work on immunoglobulin product to treat COVID-19

Australian biotech firm CSL Ltd said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus.

UPDATE 1-Australia's CSL posts 8% rise in H1 profit; raises FY outlook

Australian biotech company CSL Ltd posted an 8% rise in first-half earnings on Wednesday and raised its full-year profit forecast as it benefits from a move to distribute its own products in China.

Australia's CSL posts 8% rise in H1 profit; raises FY outlook

Australian biotech company CSL Ltd on Wednesday posted an 8% rise in first-half profit and raised its earnings forecast for the full year, helped by strong demand for its immunoglobulin (IG) products.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up